Experimental cancer drug shows promise
The drug, geranylgeranyltransferase inhibitor GGTI-2418 suppresses a new defective PTEN cancer pathway, researchers have discovered. …read more
The drug, geranylgeranyltransferase inhibitor GGTI-2418 suppresses a new defective PTEN cancer pathway, researchers have discovered. …read more